Master Alliance Provisions Guide (MAPGuide)

CEPI – Dynavax, COVID-19 Material Reservation Agreement

  • Equitable Access | Access plans & principles

<p><span style=”textdecoration: underline;”><b>Recitalsb>span>p>
<p><span style=”fontweight: 400;”>Whereas, CEPIs mission is to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for affected populations during outbreaks;span>p>
<p><span style=”fontweight: 400;”>Whereasspan><b>, b><span style=”fontweight: 400;”>CEPI has entered or may enter in the future into legal agreements with certain third parties (each, aspan><b><i>CEPI Partneri>b><span style=”fontweight: 400;”>”) regarding the funding of development and manufacturing initiatives of vaccines for COVID19span>p>
<p><span style=”fontweight: 400;”>Whereasspan><b>, b><span style=”fontweight: 400;”>to further its mission, CEPI desires to advance an interestfree, forgivable, unsecured loan to cover the costs of at risk manufacture of specified quantities of the CpG 1018 adjuvant and to reserve such quantities for purchase by CEPI Partners for use in development and manufacturing of vaccines against COVID19; [&#8230;]span>p>
<p><span style=”textdecoration: underline;”><strong>4. Compliance and Regulatorystrong>span>p>
<p><b>4.2 CEPI Third Party Code. b><span style=”fontweight: 400;”>The CEPI Third Party Code is a statement of CEPIs values and of the policies, practices and principles applicable to recipients of any funds from CEPI.span>p>
<p style=”paddingleft: 40px;”>(a) <span style=”fontweight: 400;”>Dynavax acknowledges the statement of CEPIs values in Section 1 of the Code.span>p>
<p style=”paddingleft: 40px;”>(b) <span style=”fontweight: 400;”>Dynavax acknowledges CEPIs expectation that Dynavax shall adhere to business practices, ethical principles and legal requirements that are at least substantially similar to those described inSections 2 to 10 of the Code.span>p>
<p style=”paddingleft: 40px;”>(c) <span style=”fontweight: 400;”>Dynavax shall comply with the requirements for reporting compliance concerns and misconduct to CEPI (Sections 4 and 11 of the Code).span>p>
<p style=”paddingleft: 40px;”>(d) <span style=”fontweight: 400;”>Dynavax shall cooperate as may be requested by CEPI in the submission of information related to Project activities and expenditures in accordance with the International Aid Transparency Initiative (Section 12 of the Code).span>p>
<p style=”paddingleft: 40px;”>(e) <span style=”fontweight: 400;”>Dynavax shall comply with CEPIs Equitable Access Policy.span>p>
<p style=”paddingleft: 40px;”>(f) <span style=”fontweight: 400;”>To the extent applicable to the Project, Dynavax shall comply with CEPIs Animals in Research Policy.span>p>
<p style=”paddingleft: 40px;”>(g) <span style=”fontweight: 400;”>To the extent applicable to the Project, Dynavax may rely upon its own substantially similar policies and principles so as to comply with: (i) CEPIs Clinical Trials Policy; (ii) CEPIs Managing Conflicts Of Interest Policy; (iii) CEPIs Scientific Integrity Policy; and (iv) CEPIs Travel and Expenses Policy.span>p>